M. Takeda

发表

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

P. Jänne, F. Cappuzzo, K. Okuno, 2011, Science Translational Medicine.

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA

S. Toyooka, K. Mimori, Y. Yatabe, 2021, Cancer science.

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib

I. Okamoto, K. Nakagawa, M. Takeda, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Ying Cheng, M. Satouchi, He-long Zhang, 2022, International Journal of Clinical Oncology.

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.

Kaoru Tanaka, K. Nishio, K. Doi, 2019, The Journal of clinical investigation.

Clinical outcome of node‐negative oligometastatic non–small cell lung cancer

Y. Nishimura, T. Mitsudomi, A. Kato, 2016, Thoracic cancer.

Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.

K. Nishio, K. Okamoto, M. Takeda, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer.

Y. Nishimura, T. Okuno, K. Nakagawa, 2017, Oncotarget.

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer

R. Kaiser, K. Azuma, I. Okamoto, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kaoru Tanaka, K. Azuma, I. Okamoto, 2013, Cancer Chemotherapy and Pharmacology.

Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer

T. Yamanaka, M. Okada, T. Mitsudomi, 2015, Clinical Cancer Research.

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.

K. Nishio, J. Tanizaki, K. Nakagawa, 2016, Lung cancer.

Prognostic Impact of Minimal Pericardial Effusion in Patients With Advanced Non–small‐cell Lung Cancer

Kaoru Tanaka, K. Nakagawa, Y. Chiba, 2017, Clinical lung cancer.

Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.

I. Okamoto, K. Nakagawa, K. Yonesaka, 2010, Lung cancer.

A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.

Y. Nishimura, I. Okamoto, K. Okamoto, 2014, Japanese journal of clinical oncology.

Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.

Kaoru Tanaka, J. Tanizaki, K. Nakagawa, 2016, Lung cancer.

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer.

Y. Nishimura, I. Okamoto, K. Nakagawa, 2011, Lung Cancer.

Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.

I. Okamoto, K. Nakagawa, M. Takeda, 2011, Lung cancer.

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

M. Nishio, T. Seto, T. Hida, 2021, Cancer science.

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer

K. Nishio, K. Nakagawa, S. Rothenberg, 2021, JCO precision oncology.

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.

I. Okamoto, K. Nakagawa, M. Takeda, 2015, Lung cancer.

O1-10-3Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

I. Okamoto, K. Nakagawa, M. Takeda, 2015 .

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

M. Fukuoka, K. Nishio, I. Okamoto, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR

Y. Hasegawa, K. Nakagawa, M. Takeda, 2017, ESMO Open.

Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity

K. Nakagawa, M. Takeda, H. Hayashi, 2016, Investigational New Drugs.

Implications of the success of EGFR-targeted therapy in advanced non–small cell lung cancer for its application to the adjuvant setting

M. Takeda, 2020, Journal of thoracic disease.

Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma

K. Nishio, I. Okamoto, J. Tanizaki, 2012, Acta oncologica.

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical lung cancer.

Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.

M. Fukuoka, I. Okamoto, K. Nakagawa, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.

M. Fukuoka, I. Okamoto, K. Nakagawa, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy

M. Takeda, S. Okazaki, Y. Yoshii, 2021, Life.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)

H. Aburatani, H. Ueno, S. Toyooka, 2020, International Journal of Clinical Oncology.

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

M. Okada, Y. Ohe, C. Morimoto, 2021, JTO clinical and research reports.

BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer

Pham Nguyen Quy, K. Nishio, M. Muto, 2020, Pancreas.

An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy

K. Goto, H. Kenmotsu, A. Sarashina, 2018, Cancer Chemotherapy and Pharmacology.

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?

K. Nakagawa, M. Takeda, H. Kanemura, 2020, Translational lung cancer research.

Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.

Toshio Shimizu, Kaoru Tanaka, K. Okamoto, 2016, Anti-cancer drugs.

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer

T. Okuno, K. Nakagawa, Y. Chiba, 2018, The oncologist.

Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer

T. Kudo, I. Okamoto, K. Nakagawa, 2013 .

Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary

K. Eguchi, T. Nishidate, K. Hirata, 2015, International Journal of Clinical Oncology.

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Toshio Shimizu, K. Fukuoka, L. Vaickus, 2016, Cancer Chemotherapy and Pharmacology.

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2020, British Journal of Cancer.

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, Y. Tanigawara, 2012, Oncology reports.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

T. Yamanaka, M. Okada, A. Kubo, 2015 .

Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.

Y. Nishimura, Kaoru Tanaka, T. Satoh, 2013, Anticancer research.

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.

A. Drilon, Y. Ohe, J. Wolf, 2022, The Lancet. Oncology.

Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection

Kaoru Tanaka, K. Okamoto, K. Nakagawa, 2014, PloS one.

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

J. Tanizaki, K. Nakagawa, K. Yonesaka, 2019, Cancer medicine.

A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer

K. Nakagawa, M. Takeda, S. Nishina, 2015, BMC Research Notes.

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

J. Tanizaki, K. Nakagawa, Y. Chiba, 2016, Oncotarget.

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2022, Lung cancer.

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14

K. Nakagawa, S. Shimizu, M. Takeda, 2020, Thoracic cancer.

Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

A. Drilon, L. Bazhenova, B. Konda, 2021, Clinical Trials.

A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group.

K. Nakagawa, M. Takeda, K. Haratani, 2019, Journal of thoracic disease.

Identification of fusion transcripts in sarcoma from archival formalin‐fixed paraffin‐embedded tissues: A next‐generation sequencing approach

C. Ohbayashi, N. Sawabata, M. Miyake, 2022, Pathology international.

Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.

Y. Ohe, C. Morimoto, Y. Kaneko, 2019, Lung cancer.

Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis

K. Nakagawa, M. Takeda, 2016 .

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

N. Crawford, K. Goto, M. Uno, 2023, Cancer medicine.

Yolk Sac Tumor in a Recurrence of Colonic Adenocarcinoma With Shared Mutations in APC and TP53 Genes: A Case Report

N. Matsumura, K. Nakagawa, M. Takeda, 2022, International journal of surgical pathology.

Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report

C. Ohe, M. Takeda, Y. Uemura, 2022, BMC Medical Genomics.

Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).

A. Drilon, Y. Ohe, B. Konda, 2022, Journal of Clinical Oncology.

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2018, Oncotarget.

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

S. Tomida, Kaoru Tanaka, Y. Fukuda, 2020, Clinical Cancer Research.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

T. Mitsudomi, S. Tomida, Kaoru Tanaka, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter

K. Nishio, I. Okamoto, K. Nakagawa, 2014, Oncology letters.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

A. Kawada, I. Okamoto, K. Nakagawa, 2012, Japanese journal of clinical oncology.

ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model

Y. Shiratori, K. Nishio, K. Yanagihara, 2006, International journal of cancer.

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer

K. Nishio, I. Okamoto, K. Takezawa, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

Kaoru Tanaka, K. Nishio, K. Doi, 2019, Oncogenesis.

Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.

M. Takeda, H. Hayashi, K. Nakagawa, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

M. Kudo, M. Takenaka, Kaoru Tanaka, 2017, Investigational New Drugs.

Clinical development of nintedanib for advanced non-small-cell lung cancer

I. Okamoto, K. Nakagawa, M. Takeda, 2015, Therapeutics and clinical risk management.

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer

Toshio Shimizu, K. Nishio, I. Okamoto, 2020, Cancer Chemotherapy and Pharmacology.

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

K. Nakagawa, K. Yonesaka, M. Takeda, 2019, International journal of cancer.

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.

I. Okamoto, T. Tamura, K. Nakagawa, 2019, Lung cancer.

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Kaoru Tanaka, Y. Hasegawa, J. Tanizaki, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients

C. Shimizu, Y. Fujiwara, Yoon-Koo Kang, 2006, Breast Cancer Research and Treatment.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kaoru Tanaka, K. Nishio, Y. Hasegawa, 2018, Clinical Cancer Research.

Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

T. Nishidate, S. Ohtani, T. Akechi, 2020, International Journal of Clinical Oncology.

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study

R. Toyozawa, T. Seto, K. Nakagawa, 2018, Oncotarget.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

Kazutaka Nakashima, M. Kuwano, M. Ono, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

P. Jänne, K. Nishio, I. Okamoto, 2016, Oncogene.

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

Toshio Shimizu, I. Okamoto, K. Nakagawa, 2010, Investigational New Drugs.

Clinical outcome for EML 4-ALK-positive patients with advanced non-small-cell lung cancer treated with fi rst-line platinum-based chemotherapy

K. Nishio, I. Okamoto, M. Takeda, 2012 .

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Kaoru Tanaka, K. Nishio, I. Okamoto, 2015, Oncotarget.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Kaoru Tanaka, K. Nishio, K. Azuma, 2019, Scientific Reports.

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Kazuhiko Nakagawa, K. Nakagawa, M. Takeda, 2019, International journal of molecular sciences.

Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer.

K. Nakagawa, M. Takeda, 2017, Molecular and clinical oncology.

Detection of the T 790 M mutation of EGFR in plasma of advanced non – small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors ( West Japan oncology group 8014 LTR study )

T. Ohira, S. Bandoh, K. Nishio, 2016 .

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

T. Yamanaka, Y. Nakanishi, I. Okamoto, 2012, BMC Cancer.

Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement

I. Okamoto, K. Nakagawa, M. Takeda, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

K. Nishio, I. Okamoto, M. Takeda, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)

T. Ohira, K. Nishio, K. Azuma, 2020, Molecular oncology.

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study

T. Ohira, K. Nishio, K. Azuma, 2020, Cancer.

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer

Kaoru Tanaka, K. Azuma, K. Nakagawa, 2019, Thoracic cancer.

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial

T. Yamanaka, M. Okada, A. Kubo, 2016, Cancer.

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

K. Nishio, I. Okamoto, K. Nakagawa, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer

Toshio Shimizu, K. Nishio, T. Satoh, 2015, PloS one.

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.

Toshio Shimizu, K. Nishio, T. Satoh, 2015, Anticancer research.

Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease

Toshio Shimizu, K. Nishio, N. Isogai, 2016, Investigational New Drugs.

Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.

K. Nishio, K. Naoki, K. Nakagawa, 2021, Cancer biomarkers : section A of Disease markers.

New Era for Next-Generation Sequencing in Japan

Kazuko Sakai, Kazuhiko Nakagawa, Kazuya Fukuoka, 2019, Cancers.

Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474

N. Saijo, K. Nishio, H. Fukumoto, 2004, Cancer Research.

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Kaoru Tanaka, Y. Hasegawa, K. Nakagawa, 2017, JAMA oncology.

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

Kaoru Tanaka, K. Nishio, T. Satoh, 2013, Cancer science.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, H. Matsuoka, 2011, Anticancer research.

AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

N. Saijo, H. Yokote, K. Nishio, 2007, Clinical Cancer Research.

Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab

Kaoru Tanaka, J. Tanizaki, K. Nakagawa, 2017, ESMO Open.

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study

K. Yonemori, K. Tamura, T. Koyama, 2022, Investigational New Drugs.

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

K. Nishio, I. Okamoto, H. Yamaguchi, 2011, British Journal of Cancer.

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Young Hak Kim, S. Matsumoto, M. Maemondo, 2018, Cancer science.

Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib.

M. Takeda, H. Hayashi, H. Kaneda, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.

K. Nakagawa, K. Yonesaka, M. Takeda, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2021, International Journal of Clinical Oncology.

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

K. Nishio, K. Nakagawa, M. Takeda, 2019, Clinical breast cancer.

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)

Kaoru Tanaka, K. Nishio, H. Matsuoka, 2022, The oncologist.

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed

K. Nishio, K. Nakagawa, M. Takeda, 2019, OncoTargets and therapy.

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

Kazuko Sakai, Taroh Satoh, Kazuhiko Nakagawa, 2011, Biochemical and biophysical research communications.

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

K. Nishio, T. Satoh, I. Okamoto, 2015, Oncotarget.